

DAFTAR PUSTAKA

- ADA. (2015). Standards Of Medical Care In Diabetes 2015 Abridged For Primary Care Providers. Diabetes Care.
- ADA. (2022). Standards Of Medical Care In Diabetes 2022 Abridged For Primary Care Providers. Diabetes Care.
- Aedi, N. (2010). Pengolahan dan Analisis Data Hasil Penelitian. Bandung: Universitas Pendidikan Indonesia.
- Amin, N. F., Garancang, S., Abunawas, K., Makassar, M., Negeri, I., & Makassar, A. (2023). Konsep Umum Populasi dan Sampel Dalam Penelitian. *14*(1), 15–31.
- Arini & Dwipayana, I. M. P. (2020). *Hubungan Kadar HbA1c terhadap Terapi Obat Anti Diabetes Oral Dan Kombinasi Obat Anti Diabetes Oral- Insulin Pada Penderita DM Tipe 2 Di Poliklinik Diabetes RSUP Sanglah Denpasar Tahun 2016. Jurnal Medika Udayana*, *9*(9), 94–98.
- Artini, K. S., Listyani, T. A., & Puspitasari, G. (2023). *Rasionalitas Penggunaan Obat Antidiabetes Pada Pasien DM Tipe 2 Pasien Rawat Jalan di RSUD Dr. Moewardi Surakarta. MEDFARM: Jurnal Farmasi Dan Kesehatan*, *12*(1), 9–18.
- Decroli, E. (2019). Diabetes Melitus Tipe 2. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas.
- Franek, E., Haluz, M., Var, S. C., & Christiansen, J. S. (2015). *Research : Treatment Twice-daily Insulin Degludec / Insulin Aspart Provides Superior Fasting Plasma Glucose Control and A Reduced Rate Of Hypoglycaemia Ompared With Biphasic Insulin Aspart 30 In Insulin-na Ive Adults With Type 2 Diabetes*. 497–505.
- Fulcher, G. R., Christiansen, J. S., Bantwal, G., Polaszewska-Muszynska, M., Mersebach, H., Andersen, T. H., & Niskanen, L. K. (2014). *Comparison of Insulin Degludec/ Insulin Aspart and Biphasic Insulin Aspart 30 In Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat To Target Trial*. *Diabetes Care*, *37*(8), 2084–2090.
- IDF. (2019). IDF Diabetes Atlas 9th Edition. Belgium: International Diabetes Federation.
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). *Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to A Position Statement Of The American*


Diabetes Association And The European Association For She Study Of Diabetes. Diabetes Care.

- Kahn, S. E., Cooper, M. E., & Prato, S. Del. (2014). *Pathophysiology and Treatment of Type 2 Diabetes: Perspectives On The Past, Present and Future.* *The Lancet*, 383(9922), 136–137.
- Kesavadev, J., Gowda, A., Kumar, H., Yalamanchi, S. R., Lodha, S., Singh, K. P., Basu, D., Asirvatham, A., Shah, N., Pathan, M. K., Revanna, M., & Mukherjee, J. J. (2021). *Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus Over a Period Of 1 Year During Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment).* *Medical Sciences (Basel, Switzerland)*, 10(1).
- Khairinnisa, A., & Yusmaini, H. H. (2020). *Perbandingan Penggunaan Glibenclamid-Metformin dan Glimepirid-Metformin Terhadap Efek Samping Hipoglikemia Pasien Diabetes Melitus Tipe-2 di Kota* Seminar Nasional Riset Kedokteran (SENSORIK).
- PERGUB. (2013). Peraturan Gubernur Kalimantan Selatan Nomor 054 Tahun 2013. Kalimantan Selatan.
- PERKENI. (2019). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2019. Indonesian Endocrinology Society.
- PERKENI. (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Indonesian Endocrinology Society.
- Putri, A. E., Soenarno, S. M., & Suryana, A. (2022). *Analisis Efikasi Diri dalam Pembelajaran Biologi di SMK Bunda Auni.* *EduBiologia: Biological Science and Education Journal.*
- Rimadani, L. D. (2022). Perbandingan Efektivitas Penurunan Kadar Glukosa Darah Insulin Levemir® dan Insulin Ryzodeg® Pada Pasien Diabetes Mellitus Tipe II Di RSUD Ulin Banjarmasin. *Skripsi.* Program Sarjana, Universitas Borneo Lestari, Banjarbaru. (tidak dipublikasikan)
- RISKESDAS. (2018). Hasil Riset Kesehatan Dasar 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian RI.
- Samuel, V. T., & Shulman, G. I. (2016). *The Pathogenesis of Insulin Resistance: Integrating Signaling Pathways and Substrate Flux.* *Journal of Clinical Investigation*, 126(1), 12–22.
- Tonolo, G. (2021). *Sex-Gender Awareness in Diabetes.* *Diabetology*, 2(2), 117–122.

- Wati, H., Astuti, K. I., Ramadhani, S., Kurniawan, G., Rahmadina, A., & Wahyunita, S. (2023). *Comparison of Plasma Glucose and HbA1c Levels With Glargine and Detemir Insulin in Diabetes Mellitus 2 Patients at Ulin Regional Public Hospital, Banjarmasin*. *Jurnal Ilmiah Farmasi*, 01(01), 44–49.
- Wikannanda, I. A. A. D., Sari, N. L. P. E. K., & Aryastuti, A. A. S. A. (2023). *Gambaran Penggunaan Terapi Kombinasi Oral Metformin-Sulfonilurea pada Pasien DM Tipe 2 di Denpasar*. *E-Journal AMJ (Aesculapius Medical Journal)*, 3(2), 224–232.

LAMPIRAN

Lampiran 1. Surat Izin Studi Pendahuluan




YAYASAN BORNEO LESTARI
UNIVERSITAS BORNEO LESTARI
FAKULTAS FARMASI

Jl. Kelapa Sawit 8 Bumi Berkat Telp. (0511) 4783717 Kel. Sei. Besar Kec. Banjarbaru Selatan Kode Pos 70714
www.unbl.ac.id - email: fakultas.farmasiunbl@gmail.com

Banjarbaru, 7 November 2023

Nomor : 03 /UNBL/FF/SIF/AKD.09/1123
Lampiran : -
Perihal : Izin Melakukan Studi Pendahuluan dan Observasi Data

Kepada Yth.
Pimpinan RSUD Ulin Banjarmasin
di Tempat

Dengan hormat,

Sehubungan dengan diadakannya kegiatan penelitian berupa Skripsi Mahasiswa pada Semester Ganjil TA. 2023/2024 Program Studi Sarjana Farmasi Fakultas Farmasi Universitas Borneo Lestari (UNBL), maka dengan ini memohon izin untuk mahasiswa/i berikut :

NO	NIM	NAMA MAHASISWA	JUDUL SKRIPSI
1	SF20056	M. Raffyqurrahman	Perbandingan Tekanan Darah Pada Pasien Diabetes Melitus Tipe 2 Disertai Hipertensi di RSUD Ulin Banjarmasin
2	SF20067	Noor Annida F	Perbandingan Kadar HbA1c Pada Pasien Diabetes Melitus Tipe 2 Disertai Hipertensi di RSUD Ulin Banjarmasin
3	SF20130	Nuha Afifah A	Perbandingan Kadar Gula Darah Puasa (GDP) dan Kadar Glukosa Darah 2 Jam Post Prandial (GD2PP) Pada Pasien Diabetes Melitus Tipe 2 Disertai Hipertensi di RSUD Ulin Banjarmasin

Dengan ini bertujuan untuk menanyakan perihal berikut :

1. Data Rekam Medis Pasien Diabetes Melitus tipe 2 disertai Hipertensi di RSUD Ulin Banjarmasin

Demikian surat permohonan ini kami sampaikan, atas perhatian dan perkenannya kami ucapkan terimakasih.



apt. Egi Restiana Rusida, M.Kes.
NIP. 197211016

Lampiran 2. Surat Persetujuan Studi Pendahuluan



PEMERINTAH PROVINSI KALIMANTAN SELATAN
RUMAHSAKITUMUMDAERAHULIN
Jl. Jend. A. Yani No. 43 Telp: 3257472 / 3252180 Fax: 3252229
BANJARMASIN



SURAT IZIN PENDAHULUAN
No. 93/S1.Far/Litbang/RSUDU/XI/2023

Sebagaimana Surat Rekomendasi Penerbitan Surat Izin Studi Pendahuluan/Pengambilan Data Komisi Etik RSUD Ulin Banjarmasin; Nomor: 92/XI-Reg ND Riset/RSUD/23; Tanggal 18 November 2023 ; Perihal : Rekomendasi Penerbitan Surat Izin Studi Pendahuluan, bahwa studi pendahuluan/pengambilan data dimaksud pada prinsipnya dapat disetujui dengan data mahasiswa (i) / pengumpul data sebagai berikut:

Nama : M. Raffyqurrahman
Jabatan : Peneliti
Institusi : Universitas Borneo Lestari
Status : Mahasiswa/ S1-Farmasi
Judul Penelitian : Perbandingan Tekanan Darah Pada Pasien Diabetes Melitus Tipe 2 Disertai Hipertensi di RSUD Ulin Banjarmasin.
Waktu Penelitian : November s/d Januari 2024

Demikian surat izin penelitian ini dibuat agar dapat dipergunakan sebagaimana mestinya.

Banjarmasin, 18 November 2023

a.n. Direktur
Wakil Direktur Penunjang Non Medik,
Hukum Dan Diklit,

Thaufik Hidayat, S.Sos. M.Si
Pembina Utama Muda
NIP. 19720621199101 1 001

Lampiran 3. Surat Izin Penelitian dari RSUD Ulin Banjarmasin

PEMERINTAH PROVINSI KALIMANTAN SELATAN
RUMAH SAKIT UMUM DAERAH ULIN
Jl. Jend. A. Yani No. 43 Telp. 3257472 / 3252180 Fax. 3252229
BANJARMASIN

**SURAT IZIN PENELITIAN**

No. 17/S1.Far/Litbang/RSUDU/III/2024

Sebagaimana Surat dari Dekan Fakultas Farmasi Universitas Borneo Lestari Banjarbaru, Nomor : 185/UNBL/FF/SIF/AKD.09/0224, Tanggal ; 01 Februari 2024, Perihal; Permohonan Izin Penelitian. Selanjutnya berdasarkan Surat Rekomendasi Komisi Etik Banjarmasin No.16/II-Reg Riset/RSUDU/2024, tanggal 15 Februari 2024 bahwa penelitian dimaksud pada prinsipnya dapat disetujui, dengan peneliti sebagai berikut :

Nama : Muhammad Raffyqurrahman
Jabatan : Peneliti
Institusi : Universitas Borneo Lestari
Status : Mahasiswa/ S1-Farmasi
Judul Penelitian : Perbedaan Nilai Kadar GDP dan HbA1c Pada Pasien Diabetes Mellitus Tipe II Yang Diberikan Obat Hipoglimik Oral (OHO) + Insulin Ryzodeg ® Vs Insulin Ryzodeg ® di RSUD Ulin Banjarmasin .
Waktu Penelitian : Februari s/d April 2024

Demikian surat izin penelitian ini dibuat agar dapat dipergunakan sebagaimana mestinya.

Banjarmasin, 20 Februari 2024

a.n. Direktur
Plt. Wakil Direktur Penunjang Non Medik,
Hukum Dan Diklit,

Dinansyah S.Sos., M.M
Pembina Utama Muda
NIP. 196702101989031012

Lampiran 4. Surat Keterangan Kelayakan Etik Penelitian



PEMERINTAH PROVINSI KALIMANTAN SELATAN
RUMAH SAKIT UMUM DAERAH ULIN
INSTALASI RISET
Jl. A. Yani 43 Telp. 3257472 / 3252180 Fax. 3252229
BANJARMASIN



SURAT KETERANGAN KELAYAKAN ETIK PENELITIAN

No. 16/II-Reg Riset/RSUDU/24

Dengan hormat.

Dengan ini Komisi etik penelitian Rumah Sakit Umum Daerah Ulin Banjarmasin telah mengkaji permohonan kelayakan etik penelitian yang diajukan oleh:

Nama Peneliti : Muhammad Raffyqurrahman
NIM : SF20059
Program Studi : S1-Farmasi
Instansi : Universitas Borneo Lestari
Judul Penelitian : "Perbedaan Nilai Kadar GDP dan HbA1c Pada Pasien Diabetes Mellitus Tipe II Yang Diberikan Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg ® Vs Insulin Ryzodeg ® di RSUD Ulin Banjarmasin "

Pada tanggal : 15 Februari 2024

Dengan Hasil :

- Layak etik
- Layak etik dengan usul perbaikan
- Tidak layak etik

Demikian surat keterangan ini diberikan untuk dapat dipergunakan sebagaimana mestinya.

Banjarmasin, 15 Februari 2024

Komisi Etik Penelitian
RSUD Ulin Banjarmasin



Khairil Asadi, S.Kep.M.MKes
NIP. 19780403 200701 1 024

Lampiran 5. Surat Keterangan Selesai Penelitian



PEMERINTAH PROVINSI KALIMANTAN SELATAN
RUMAH SAKIT UMUM DAERAH ULIN
INSTALASI RISET
Jl. A. Yani 43 Telp. 3257472 / 3252180 Fax. 3252229
BANJARMASIN



SURAT KETERANGAN SELESAI PENELITIAN

No. 04/VI-Reg Riset/RSUDU/24

Dengan hormat.

Dengan ini Komisi etik penelitian Rumah Sakit Umum Daerah Ulin Banjarmasin telah mengkaji permohonan kelayakan etik penelitian yang diajukan oleh:

Nama Peneliti : Muhammad Raffyqurrahman
 NIM : SF20059
 Program Studi : S1-Farmasi
 Instansi : Universitas Borneo Lestari
 Judul Penelitian : "Perbedaan Nilai Kadar GDP dan HbA1c Pada Pasien Diabetes Mellitus Tipe II Yang Diberikan Obat Hipoglimik Oral (OHO) + Insulin Ryzodeg ® Vs Insulin Ryzodeg ® di RSUD Ulin Banjarmasin "

Telah selesai melaksanakan penelitian pada bulan Juni 2024

Demikian surat keterangan ini diberikan untuk dapat dipergunakan sebagaimana mestinya.

Banjarmasin, 13 Juni 2024

Komis Etik Penelitian
 RSUD Ulin Banjarmasin

Khairil Anas, Kep.M.MKes
 NIP. 19780403 200701 1 024

Lampiran 6. Hasil Analisis Data Menggunakan SPSS

A. Karakteristi Subjek

1) Karakteristik Jenis Kelamin

Jenis Kelamin * Terapi Obat Crosstabulation

		Terapi Obat		Total	
		Ryzodeg	Ryz+OHO		
Jenis Kelamin	Laki-Laki	Count	8	10	18
		% of Total	12.1%	15.2%	27.3%
	Perempuan	Count	25	23	48
		% of Total	37.9%	34.8%	72.7%
Total		Count	33	33	66
		% of Total	50.0%	50.0%	100.0%

2) Karakteristik Usia

Usia * Terapi Obat Crosstabulation

		Terapi Obat		Total		
		Ryzodeg	Ryz+OHO			
Usia	25-44	Count	1	4	5	
		% of Total	1.5%	6.1%	7.6%	
	45-54	Count	3	8	11	
		% of Total	4.5%	12.1%	16.7%	
	55-65	Count	11	10	21	
		% of Total	16.7%	15.2%	31.8%	
	66-74	Count	14	9	23	
		% of Total	21.2%	13.6%	34.8%	
	75-90	Count	4	2	6	
		% of Total	6.1%	3.0%	9.1%	
	Total		Count	33	33	66
			% of Total	50.0%	50.0%	100.0%

B. Frekuensi Penggunaan Obat Hipoglikemik Oral (OHO)

		Kombinasi Obat			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Insulin Ryzodeg + Metformin	24	72.7	72.7	72.7
	Insulin Ryzodeg + Acarbose	5	15.2	15.2	87.9
	Insulin Ryzodeg + Gliquidone	1	3.0	3.0	90.9
	Insulin Ryzodeg + Glimepiride	3	9.1	9.1	100.0
	Total	33	100.0	100.0	

C. Uji Normalitas

1) Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg®

	Tests of Normality					
	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	Df	Sig.
Pretest	.148	33	.066	.938	33	.060
Posttest	.183	33	.007	.938	33	.060

a. Lilliefors Significance Correction

2) Insulin Ryzodeg®

	Tests of Normality					
	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	Df	Sig.
Pretest	.179	33	.009	.947	33	.111
Posttest	.107	33	.200 [*]	.966	33	.368

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Kesimpulan: Data *pre-test* dan *post-test* kedua perlakuan terdistribusi normal ($\text{sig} > 0,05$).

3) Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg® (*Post*) dan Insulin Ryzodeg® (*Post*)

		Tests of Normality					
		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Perlakuan Terapi	Statistic	Df	Sig.	Statistic	Df	Sig.
Hasil HbA1c	Terapi Insulin Ryz	.107	33	.200*	.966	33	.368
	Terapi OHO+Insulin Ryz	.183	33	.007	.938	33	.060

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

D. Uji Homogenitas

		Test of Homogeneity of Variance			
		Levene Statistic	df1	df2	Sig.
Hasil HbA1c	Based on Mean	2.386	1	64	.127
	Based on Median	1.147	1	64	.288
	Based on Median and with adjusted df	1.147	1	54.691	.289
	Based on trimmed mean	2.318	1	64	.133

Kesimpulan: Data *post-test* kedua perlakuan terdistribusi secara homogen ($\text{sig} > 0,05$).

E. Uji Paired Sample T-test

1. Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg®

		Paired Samples Test							
		Paired Differences		95% Confidence Interval of the Difference		t	df	Sig. (2-tailed)	
	Mean	Std. Deviation	Std. Error Mean	Lower	Upper				
Pair1	Pre Test- PostTest	1.5636	2.0208	.3518	.8471	2.2802	4.445	32	.000

ativat
Go to Set

2. Insulin Ryzodeg®

Paired Samples Test									
Paired Differences									
Pair1	Pre test - Post test	Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference		t	df	Sig. (2-tailed)
					Lower	Upper			
		1.0545	1.3328	.2320	.5820	1.5271	4.545	32	.000

Kesimpulan: Data paired sample t-test kedua perlakuan terapi dapat dikatakan memiliki pengaruh penggunaan terapi terhadap penurunan HbA1c pada pasien Diabetes Mellitus tipe II (Sig 2-tailed < 0,05).

F. Uji Independent Sample T-test

Independent Samples Test										
		Levene's Test for Equality of Variances			t-test for Equality of Means					
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
Hasil HbA1c	Equal variances assumed	2.386	.127	-3.340	64	.001	-1.5333	.4591	-2.4505	-.6162
	Equal variances not assumed			-3.340	61.515	.001	-1.5333	.4591	-2.4512	-.6154

Kesimpulan: Data independent sample t-test Adanya perbedaan yang signifikan pada nilai kadar HbA1c pada pasien diabetes mellitus tipe II yang diberikan OHO + insulin ryzodeg® vs insulin ryzodeg® di RSUD Ulin Banjarmasin (sig 2-tailed < 0,05).

Lampiran 7. Rekapitan Data Rekam Medis Pasien Kombinasi Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg®

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
1	OHRYZ 01	68	Pr	10,2%	9,1%	Acarbose 50mg; clopidogrel 75mg; digoxin tab; herbesser cd 200kaps; candesartan 16mg; Pen Needle 32,5x4; Ryzodeg flex touch.
2	OHRYZ 02	69	Pr	11,9%	12,5%	Metformin 500mg; alprazolam 0,5mg; fenofibrate 300mg; gabapentin 300mg; bisoprolol 5mg; amlodipin 10mg; candesartan 16mg; Pen Needle 32,5x4; Ryzodeg flex touch.
3	OHRYZ 03	67	Lk	13,0%	12,4%	Metformin 500mg; simvastatin 20mg; avodart tab; tamsulosin 0,4mg; candesartan 8mg; Pen Needle 32,5x4; Ryzodeg flex touch.
4	OHRYZ 04	70	Pr	7,1%	8,4%	Acarbose 100mg; candesartan 8mg; Pen Needle 32,5x4; Ryzodeg flex touch.
5	OHRYZ 05	65	Pr	11,7%	8,9%	Metformin 500mg; ramipril 10mg; amlodipin 10mg; Pen Needle 32,5x4; Ryzodeg flex touch.
6	OHRYZ 06	76	Pr	8,6%	8,4%	Fenofibrate 300mg kap; herbesser cd 200kaps; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; candesartan 8mg.
7	OHRYZ 07	76	Lk	12,5%	11,7%	Acarbose 100mg; amlodipin 10mg; simvastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch.
8	OHRYZ 08	70	Lk	12,7%	9,1%	Aspilet Tab; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch; candesartan 16mg.
9	OHRYZ 09	74	Pr	11,8%	10,7%	atorvastatin 20mg; lansoprazole 30mg; metformin 500mg; tanapress 10mg; calcium carbonat 500mg; herbesser cd 200 kaps; Pen Needle 32,5x4; Ryzodeg flex touch.
10	OHRYZ 10	71	Pr	8,7%	7,9%	amlodipin 10mg; atorvastatin 20mg; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch; fenofibrate 100mg; risedronate sodium 35mg.
11	OHRYZ 11	60	Pr	8,9%	8,4%	Gabapentin 300 mg kap; lansoprazole 30mg; allopurinol 10mg; clopidogrel 75mg; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch; candesartan 16mg; bisoprolol 2,5mg.
12	OHRYZ 12	74	Lk	12,0%	10,4%	atorvastatin 20mg; cetirizine 10mg; clopidogrel 75mg; lisinopril 10mg; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch; avodart tab; tamsulosin 0,4mg

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
13	OHRYZ 13	69	Pr	13,3%	12,7%	atorvastatin 20mg; gabapentin 300mg; vit. B kompleks; calcium carbonate 500mg; candesartan 8mg; acarbose 50mg; Pen Needle 32,5x4; Ryzodeg flex touch;
14	OHRYZ 14	58	Pr	14,9%	9,5%	atorvastatin 20mg; gabapentin 300mg; gliquidone 30mg; Pen Needle 32,5x4; Ryzodeg flex touch; amlodipin 10mg; candesartan 8mg.
15	OHRYZ 15	51	Lk	16,7%	12,8%	gabapentin 300mg; simvastatin 20mg; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch.
16	OHRYZ 16	52	Pr	14,4%	9,1%	Metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch; paracetamol 500mg; gabapentin 100mg caps.
17	OHRYZ 17	49	Pr	8,3%	7,5%	Amlodipin 5mg; candesartan 16mg; simvastatin 20mg; metformin 850mg; Pen Needle 32,5x4; Ryzodeg flex touch.
18	OHRYZ 18	60	Lk	15,2%	9,0%	Aspilet Tab; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; candesartan 16mg; simvastatin 20mg, gabapentin 100mg caps; amlodipin 10mg.
19	OHRYZ 19	44	Pr	8,4%	7,5%	Cotrimoxazole 480mg; paracetamol 500mg; amlodipin 10mg; candesartan 16mg; galvus 50mg; glimepiride 2mg; Pen Needle 32,5x4; Ryzodeg flex touch;
20	OHRYZ 20	51	Pr	20,1%	14,7%	Acarbose 50mg; Pen Needle 32,5x4; Ryzodeg flex touch; gabapentin 300mg; simvastatin 10mg; candesartan 8mg.
21	OHRYZ 21	56	Pr	12,3%	11,0%	Lansoprazol 30mg; sucralfat syr 100ml; atorvastatin 20mg; isosorbite dinitrat 5mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
22	OHRYZ 22	57	Pr	13,8%	13,0%	atorvastatin 20mg; gabapentin 300mg; lansoprazole 30mg; genoint salep kulit; glimepiride 2mg; Pen Needle 32,5x4; Ryzodeg flex touch
23	OHRYZ 23	51	Pr	8,3%	7,4%	amitriptiline 225mg; gabapentin 300mg; simvastatin 20mg; vit. B kompleks; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch
24	OHRYZ 24	32	Pr	13,3%	10,4%	allopurinol 100mg; simvastatin 20mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
25	OHRYZ 25	51	Pr	8,5%	8,4%	Amlodipin 10mg; cetirizine 10mg; propranolol 10mg; simvastatin 20mg; candesartan 16mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
26	OHRYZ 26	63	Pr	10,9%	10,1%	Metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; simvastatin 20mg; amlodipin 10mg; candesartan 16mg.
27	OHRYZ 27	40	Lk	7,5%	7,8%	gabapentin 300mg kap; simvastatin 20mg; amlodipin 10mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
28	OHRYZ 28	56	Pr	9,7%	12,4%	Cartylo 80mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; simvastatin 20mg; amlodipin 10mg; candesartan 16mg.
29	OHRYZ 29	63	Lk	12,1%	8,8%	ramipril 2,5mg; simvastatin 20mg; amlodipin 10mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
30	OHRYZ 30	32	Pr	8,7%	9,0%	simvastatin 20mg; cetirizine 10mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
31	OHRYZ 31	51	Pr	14,0%	12,8%	atorvastatin 20mg; gabapentin 300mg; vildagliptin 50mg; lisinopril 5mg; tanapres 5mg; glimepiride 2mg; Pen Needle 32,5x4; Ryzodeg flex touch
32	OHRYZ 32	60	Lk	8,5%	6,8%	metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; propanolol 40mg; spironolactone 100mg; entecavir monohidrate 0,5mg.
33	OHRYZ 33	54	Lk	13,1%	10,9%	amlodipin 10mg; atorvastatin 20mg; metformin 500mg; Pen Needle 32,5x4; Ryzodeg flex touch; bisoprolol 2,5mg; candesartan 16mg; gabapentin 300mg.

Lampiran 8. Rekapitan Data Rekam Medis Pasien Monoterapi Insulin Ryzodeg®

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
1	Ryz 01	75	Pr	8,0%	5,8%	Gabapentin 300 mg; Lisinopril 10 mg; Simvastatin 20 mg; Pen Needle 32,5x4; Ryzodeg flex touch; Amlodipin 10 mg.
2	Ryz 02	63	Pr	13,4%	8,6%	Cetirizine 10 mg; Gabapentin 300 mg; Simvastatin 20 mg; Pen Needle 32,5x4; Ryzodeg flex touch; Calcium Carbonate 500 Ristonat Tab
3	Ryz 03	70	Lk	9,8%	8,9%	Aspilets Tab; Simvastatin 20 mg tab; Pen Needle 32,5x4; Ryzodeg flex touch; Avodart Tab; Tamsulosin 0,4 mg Tab.
4	Ryz 04	64	Pr	11,0%	10,7%	Pen Needle 32,5x4; Ryzodeg flex touch; Atorvastatin 20 mg; lansoprazole 30 mg; gabapentin 100 mg; Calcium carbonate 500; Ristonat Tab.
5	Ryz 05	74	Pr	8,0%	7,2%	Gabapentin 300 mg; Pen Needle 32,5x4; Ryzodeg flex touch; Calcium Carbonate 500; Ristonat Tab; Candesartan 16 mg.
6	Ryz 06	66	Pr	8,1%	6,8%	Cilostazol 100 mg; Herbesser CD 200; Ramipril 2,5 mg; simvastatin 20 mg; Gabapentin; Pen Needle 32,5x4; Ryzodeg flex touch.
7	Ryz 07	66	Pr	6,3%	6,5%	Asam folat 1 mg; Aspilets Tab; Calos Chewable tab; Micardis 80 mg tab; Simvastatin 20 mg tab; Pen Needle 32,5x4; Ryzodeg flex touch.
8	Ryz 08	70	Pr	7,1%	6,4%	Amlodipin 5mg; Atorvastatin 20mg; Clopidogrel 75mg; Gabapentin 300 mg; Pen Needle 32,5x4; Ryzodeg flex touch.
9	Ryz 09	74	Lk	8,4%	7,1%	Gabapentin 300 mg; Pen Needle 32,5x4; Ryzodeg flex touch; Allopurinol 100 mg; Amlodipin 10mg ; Vit. B12 Kompleks Tab; Candesartan 16mg; Tamsulosin 0,4mg.
10	Ryz 10	65	Pr	8,9%	7,7%	Atorvastatin 20mg; Clopidogrel 75mg; Nitrokaf 2,5mg; Pen Needle 32,5x4; Ryzodeg flex touch; Bisoprolol 2,5 mg; Candesartan.
11	Ryz 11	71	Pr	9,8%	9,2%	Calos Chewable tab; Fenofibrate 300mg; simvastatin 10mg; Candesartan 16mg; Osteonate OAW; Ryzodeg flex touch.

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
12	Ryz 12	78	Pr	8,4%	8,2%	Gabapentin 300 mg; Pen Needle 32,5x4; Ryzodeg flex touch; Avodart Tab; Candesartan 8mg tab; Tamsulosin 0,4mg.
13	Ryz 13	61	Pr	13,1%	9,7%	Atorvastatin 20mg; Gabapentin 300mg; Lansoprazole 30mg; Amlodipin 5mg; Candesartan 8mg; Simvastatin 20mg; Na. Diklofenac 50mg; Pen Needle 32,5x4; Ryzodeg flex touch.
14	Ryz 14	79	Pr	6,3%	6,6%	Alprazolam 0,5mg; Amlodipin 10mg; Clopidogrel 75mg; Simvastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch; Osteonate OAW Tab.
15	Ryz 15	76	Pr	7,9%	8,4%	amlodipin 5mg; meloxicam 7,5mg; candesartan 8mg; Pen Needle 32,5x4; Ryzodeg flex touch.
16	Ryz 16	65	pr	8,2%	7,8%	amlodipin 10mg; atorvastatin 20mg; lansoprazole 30mg; bisoprolol 2,5mg; candesartan 16mg; Pen Needle 32,5x4; Ryzodeg flex touch.
17	Ryz 17	71	Pr	10,4%	10,1%	atorvastatin 20mg; cetirizine 10mg; codein 10mg; candesartan 116mg; betahistin e 24mg; methyl prednisolon 4mg; Pen Needle 32,5x4; Ryzodeg flex touch.
18	Ryz 18	66	Lk	7,3%	6,8%	Aspilets Tab; Nitrokaf 2,5mg; bisoprolol 5mg; ramipril 10mg; Pen Needle 32,5x4; Ryzodeg flex touch;
19	Ryz 19	71	Pr	10,4%	8,6%	Amlodipin 10mg; simvastatin 20mg; gabapentin 100mg; lansoprazole 30mg; Pen Needle 32,5x4; Ryzodeg flex touch.
20	Ryz 20	73	Lk	9,5%	9,2%	Adalat oros 30mg; atorvastatin 20mg; bisoprolol 5mg; candesartan 16mg; galvus 50mg; Pen Needle 32,5x4; Ryzodeg flex touch.
21	Ryz 21	64	Pr	7,3%	6,9%	Atorvastatin 20mg, gabapentin 100mg; asam folat 5mg, Pen Needle 32,5x4; Ryzodeg flex touch.
22	Ryz 22	67	Lk	10,7%	8,1%	Cetirizine 10mg; cotrimoxazole 480mg; gabapentin 300mg kap; candesartan 8mg; Pen Needle 32,5x4; Ryzodeg flex touch.
23	Ryz 23	55	Pr	8,4%	9,5%	Aspilet tab; simvaastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch.
24	Ryz 24	53	Pr	12,5%	11,4%	Gabapentin 300mg kap; simvastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch.

No	Kode	Umur	Jk	HbA1c		Terapi pasien
				Pre	Post	
25	Ryz 25	60	Pr	7,7%	6,0%	Amlodipin 5mg, lansoprazole 30mg kap; simvastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch; NaCl 0,9%.
26	Ryz 26	59	Pr	10,5%	10,6%	Ciprofloxacin 500mg; gabapentin 300mg kap; Na. Diklofenac 50mg; Vit. B kompleks; bisoprolol 5mg, candesartan 16mg; Pen Needle 32,5x4; Ryzodeg flex touch.
27	Ryz 27	48	Pr	7,8%	8,4%	Atorvastatin 20mg; cotrimoxazole 480mg; meloxicam 15mg; paracetamol 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
28	Ryz 28	62	Lk	14,4%	12,0%	clindamycin 300mg kap; cotrimoxazole 480mg; paracetamol 500mg; Pen Needle 32,5x4; Ryzodeg flex touch.
29	Ryz 29	60	Pr	12,2%	10,1%	Cartylo 80mg; gabapentin 300mg; simvastatin 20mg; vit. B kompleks; Pen Needle 32,5x4; Ryzodeg flex touch.
30	Ryz 30	47	Lk	11,6%	11,2%	Fenofibrate 300mg; gabapentin 300mg; simvastatin 20mg; Pen Needle 32,5x4; Ryzodeg flex touch.
31	Ryz 31	71	Lk	7,0%	6,9%	Amlodipin 10mg; Atorvasatin 20mg; cartylo 80mg; bisoprolol 5mg; candesartan 16mg, levothyroxine 100mg; Pen Needle 32,5x4; Ryzodeg flex touch.
32	Ryz 32	29	Pr	12,0%	7,9%	Amlodipin 5mg; simvastatin 10mg; Pen Needle 32,5x4; Ryzodeg flex touch.
33	Ryz 33	68	Pr	11,3%	9,6%	Amlodipin 10mg; simvastatin 20mg; candesartan 16mg; Vit. B Kompleks; Pen Needle 32,5x4; Ryzodeg flex touch.

Lampiran 9. Rekapitan Data HbA1c Insulin Ryzodeg® dan Obat Hipoglikemik Oral (OHO) + Insulin Ryzodeg®

No.	Inisial Nama	HbA1c			No.	Inisial Nama	HbA1c	
		Pre	Post				Pre	Post
1	Ryz 01	8.0	5.8		1	OHRYZ 01	10.2	9.1
2	Ryz 02	13.4	8.6		2	OHRYZ 02	11.9	12.5
3	Ryz 03	9.8	8.9		3	OHRYZ 03	13	12.4
4	Ryz 04	11.0	10.7		4	OHRYZ 04	7.1	8.4
5	Ryz 05	8.0	7.2		5	OHRYZ 05	11.7	8.9
6	Ryz 06	8.1	6.8		6	OHRYZ 06	8.6	8.4
7	Ryz 07	6.3	6.5		7	OHRYZ 07	12.5	11.7
8	Ryz 08	7.1	6.4		8	OHRYZ 08	12.7	9.1
9	Ryz 09	8.4	7.1		9	OHRYZ 09	11.8	10.7
10	Ryz 10	8.9	7.7		10	OHRYZ 10	8.7	7.9
11	Ryz 11	9.8	9.2		11	OHRYZ 11	8.9	8.4
12	Ryz 12	8.4	8.2		12	OHRYZ 12	12	10.4
13	Ryz 13	13.1	9.7		13	OHRYZ 13	13.3	12.7
14	Ryz 14	6.3	6.6		14	OHRYZ 14	14.9	9.5
15	Ryz 15	7.9	8.4		15	OHRYZ 15	16.7	12.8
16	Ryz 16	8.2	7.8		16	OHRYZ 16	14.4	9.1
17	Ryz 17	10.4	10.1		17	OHRYZ 17	8.3	7.5
18	Ryz 18	7.3	6.8		18	OHRYZ 18	15.2	9
19	Ryz 19	10.4	8.6		19	OHRYZ 19	8.4	7.5
20	Ryz 20	9.5	9.2		20	OHRYZ 20	20.1	14.7
21	Ryz 21	7.3	6.9		21	OHRYZ 21	12.3	11
22	Ryz 22	10.7	8.1		22	OHRYZ 22	13.8	13
23	Ryz 23	8.4	9.5		23	OHRYZ 23	8.3	7.4
24	Ryz 24	12.5	11.4		24	OHRYZ 24	13.3	10.4
25	Ryz 25	7.7	6.0		25	OHRYZ 25	8.5	8.4
26	Ryz 26	10.5	10.6		26	OHRYZ 26	10.9	10.1
27	Ryz 27	7.8	8.4		27	OHRYZ 27	7.5	7.8
28	Ryz 28	14.4	12.0		28	OHRYZ 28	9.7	12.4
29	Ryz 29	12.2	10.1		29	OHRYZ 29	12.1	8.8
30	Ryz 30	11.6	11.2		30	OHRYZ 30	8.7	9
31	Ryz 31	7.0	6.9		31	OHRYZ 31	14	12.8
32	Ryz 32	12.0	7.9		32	OHRYZ 32	8.5	6.8
33	Ryz 33	11.3	9.6		33	OHRYZ 33	13.1	10.9
	Rata-rata	9.5	8.5			Rata-rata	11.5485	9.98485
	SD	2.17844	1.66698			SD	2.96322	2.04376